Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?

Pfizer's stock recently hit a new 52-week high, marking a potential turnaround for the company. So far in 2023, shares have risen 20%, making Pfizer one of the top high-yield dividend stocks with a 5.8% forward dividend yield. Despite this progress, the turnaround is still in its early stages.

The company has achieved some positive results, such as revenue growth of 3% and earnings that, while slightly below GAAP expectations, exceeded Wall Street's forecasts. Sales of key drugs like Eliquis, Padcev, and Lorbrena have helped counteract the decline in sales from Pfizer's COVID-19 vaccine and treatments.

Pfizer has also been focused on cost-cutting, implementing a program since 2023 that could result in up to $6.7 billion in savings by 2029. The company recently raised its full-year guidance and adjusted earnings forecast, aligning with analyst expectations.

However, Pfizer faces challenges ahead, particularly with the expiration of patents on drugs like Eliquis and Ibrance. The company expects earnings per share (EPS) to decline slightly in 2027, but it remains optimistic about the future. If Pfizer continues to cut costs, meet sales expectations, and sees success with its pipeline, including anti-obesity drug candidates from the Metsera acquisition, there is potential for shares to climb even further.

While uncertainty remains, Pfizer's strong dividend, sustainable payout ratio, and potential for cost reduction efforts could provide investors with a stable yield and the opportunity to benefit from a potential stock price increase once the patent cliff has passed.